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RESEARCH ARTICLE Open Access
Glycation marker glucosepane increases
with the progression of osteoarthritis
and correlates with morphological and
functional changes of cartilage in vivo
Catherine Legrand1†, Usman Ahmed2,3†, Attia Anwar2, Kashif Rajpoot4, Sabah Pasha2, Cécile Lambert1,
Rose K. Davidson5, Ian M. Clark5, Paul J. Thornalley2,3, Yves Henrotin1,6 and Naila Rabbani2,3*
Abstract
Background: Changes of serum concentrations of glycated, oxidized, and nitrated amino acids and hydroxyproline and
anticyclic citrullinated peptide antibody status combined by machine learning techniques in algorithms have recently
been found to provide improved diagnosis and typing of early-stage arthritis of the knee, including osteoarthritis (OA), in
patients. The association of glycated, oxidized, and nitrated amino acids released from the joint with development and
progression of knee OA is unknown. We studied this in an OA animal model as well as interleukin-1β-activated human
chondrocytes in vitro and translated key findings to patients with OA.
Methods: Sixty male 3-week-old Dunkin-Hartley guinea pigs were studied. Separate groups of 12 animals were killed at
age 4, 12, 20, 28 and 36 weeks, and histological severity of knee OA was evaluated, and cartilage rheological properties
were assessed. Human chondrocytes cultured in multilayers were treated for 10 days with interleukin-1β. Human patients
with early and advanced OA and healthy controls were recruited, blood samples were collected, and serum or plasma
was prepared. Serum, plasma, and culture medium were analyzed for glycated, oxidized, and nitrated amino acids.
Results: Severity of OA increased progressively in guinea pigs with age. Glycated, oxidized, and nitrated amino acids were
increased markedly at week 36, with glucosepane and dityrosine increasing progressively from weeks 20 and 28,
respectively. Glucosepane correlated positively with OA histological severity (r = 0.58, p < 0.0001) and instantaneous
modulus (r = 0.52–0.56; p < 0.0001), oxidation free adducts correlated positively with OA severity (p < 0.0009–0.0062),
and hydroxyproline correlated positively with cartilage thickness (p < 0.0003–0.003). Interleukin-1β increased the release
of glycated and nitrated amino acids from chondrocytes in vitro. In clinical translation, plasma glucosepane was
increased 38% in early-stage OA (p < 0.05) and sixfold in patients with advanced OA (p < 0.001) compared with healthy
controls.
Conclusions: These studies further advance the prospective role of glycated, oxidized, and nitrated amino acids as serum
biomarkers in diagnostic algorithms for early-stage detection of OA and other arthritic disease. Plasma glucosepane,
reported here for the first time to our knowledge, may improve early-stage diagnosis and progression of clinical OA.
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Background
Osteoarthritis (OA) is a pathogenesis in movable joints
characterized by cell stress and extracellular matrix
degradation initiated by micro- and macroinjury. Patho-
genesis involves low-grade inflammation mediated by in-
nate and adaptive immunity and maladaptive repair
responses. It initially manifests in molecular changes
related to drivers of pathogenesis and culminates in
anatomic and/or physiologic derangements of increasing
severity [1].
Current diagnosis of OA is based on radiographic cri-
teria and clinical symptoms, such as joint space width,
pain, and loss of function. The related established cartil-
age lesions are irreversible with current treatments.
Magnetic resonance imaging has been applied to
early-stage OA diagnosis, but its use is limited by cost,
availability, and absence of a validated scoring system.
Measurement of soluble biomarkers in plasma or serum
offers an alternative approach for early-stage diagnosis,
assessment of progression, and therapeutic monitoring
[2]. Development of early-stage diagnosis and effective
earlier conservative interventions would likely decrease
morbidity and cost of care.
Optimum candidate biomarkers in OA are molecules or
molecular fragments present in cartilage, bone, or syno-
vium [3]. Damaging posttranslational modifications of
proteins in the joint—glycation, oxidation, and nitration—
are considered part of the pathogenic process in OA,
impairing biomechanical properties of cartilage [4]. A
source of blood-based biomarkers relevant to damaging
modifications of cartilage and other proteins are
trace-level glycated, oxidized, and nitrated amino acids
(Fig. 1), part of which originates from the arthritic joint.
We recently reported patterns of changes of these meta-
bolites in synovial fluid and plasma of patients with early
and advanced stages of OA and other arthritic disease of
Fig. 1 Protein glycation, oxidation, and nitration free adducts, bone resorption marker hydroxyproline, and citrullinated protein. For glycation,
oxidation, and nitration adduct residues of proteins, the NH3
+- and -CO2
− termini are part of the peptide backbone of the protein as -NH- and –
CO- residues, respectively
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the knee compared with subjects with good skeletal
health. Patterns of analyte change were distinctive for type
of arthritis. Data-driven combination of plasma or serum
levels of glycated, oxidized, and nitrated amino acids with
anticyclic citrullinated peptide (anti-CCP) antibody status
and hydroxyproline (Hyp) by machine learning techniques
with two different diagnostic algorithms applied sequen-
tially provided high sensitivity and specificity for diagnosis
and typing of early-stage arthritic disease [5]. The applica-
tion of this diagnostic approach may be further substanti-
ated by gaining insight into the temporal relationship of
changes in glycated, oxidized, and nitrated amino acids in
serum during development of experimental OA, where
correlation with changes in joint histology and thickness
and biomechanical properties of cartilage may be made. It
is currently unknown how levels of serum glycated,
oxidized, and nitrated proteins and amino acids change
longitudinally in experimental models of OA and how the
changes relate to morphological and functional changes of
cartilage in the developing arthritic joint. Glucosepane
(GSP) is a further major glycation-derived crosslink of
joint proteins [6, 7] that we did not study in our previous
work but was considered in the present study [5].
In this work, we studied the progression of histological
and biomechanical properties in the Dunkin-Hartley
guinea pig model of spontaneous OA. This animal
model is the gold standard for studying aging-related
OA, is recommended by the Osteoarthritis Research
Society International (OARSI), and is defined as a spon-
taneous model of OA [8, 9]. It has advantages over other
animal models in that the guinea pig knee joint structure
is similar to that of the human knee and develops OA
with many histopathological similarities to human path-
ology, related to both age and body weight [10]. The de-
velopment of OA during a younger life period than in
human subjects involves a shorter period for protein
damage adduct accumulation than in human subjects,
and hence changes in serum concentrations of glycated,
oxidized, and nitrated amino acids may be smaller than
those found in human subjects [5]. Nevertheless, serum
GSP emerged in this animal model and in an in vitro
model of chondrocyte inflammation as a key new
glycated amino acid biomarker. This translated well to
clinical early and advanced OA. This further advances
the potential role of glycated, oxidized, and nitrated
amino acids as biomarker features in diagnostic algo-
rithms for early-stage detection and typing of OA and
other arthritic disease.
Methods
Spontaneous OA in Dunkin-Hartley guinea pig
Sixty male 3-week-old Dunkin-Hartley guinea pigs, pur-
chased from Charles River Laboratories (Paris, France)
with identification by microchip, were used in the study.
They were bred under pathogen-free conditions with
free access to water. In experimental studies, they were
housed three per solid-bottom cage and fed with a
standard guinea pig chow (Special Diets Service, Essex,
England) containing vitamin C (394 mg/kg) and vitamin
D3 (1973 IU/kg), allowing 2 weeks for acclimatization.
Polyvinyl chloride pipes were added to the cages to im-
prove housing conditions and minimize stress. Separate
groups of 12 animals were sacrificed and analyzed at age
4, 12, 20, 28 and 36 weeks. There was no repeated ana-
lysis of animals in the study. The number of animals per
group was chosen according to the OARSI recommen-
dation [11]. Animal body weight and food consumption
were recorded weekly. Blood samples were collected by
intracardiac puncture under general anesthesia (sodium
pentobarbital 200 mg/kg intraperitoneally) immediately
before animals were killed. Blood samples were centri-
fuged (2000 × g, 5 minutes), and serum was stored at −
80 °C until analysis. Samples were centrifuged within 1
hour of collection. All experimental procedures and
protocols were reviewed and approved by the Institu-
tional Animal Care and Use Ethics Committee of the
University of Liège (Belgium) (reference 1648).
Histology
At the time animals were killed, cartilage samples were
processed for histological evaluation. The right knee
joint (femoral condyles and tibial plateaus) from each
animal was fixed for 24 hours in 4% paraformaldehyde,
followed by decalcification in hydrochloric acid (DC2
medium; Labonord, Templemars, France) for 4 hours at
4 °C before embedding in paraffin. The right kidney and
a piece of the liver were fixed in 4% paraformaldehyde
and embedded in paraffin.
Sections (6 μm) of the femoral condyles and tibial
plateaus were cut with a microtome in the central area
not covered by meniscus following the Cushin plane, as
recommended by OARSI [11]. Three sections at 200-μm
intervals were stained with hematoxylin, Fast Green, and
Safranin-O, and one supplementary central section was
stained with toluidine blue. Each compartment of the
section (tibial median, tibial lateral, femoral median, and
femoral lateral) was scored by two trained experts
blinded from sample identity following OARSI recom-
mendations for the guinea pig model. Briefly, the evalu-
ation considered the cartilage surface integrity (0–8), the
proteoglycan content (0–6), the cellularity (0–3), the
tidemark integrity (0–1), and the osteophyte (0–3), with
a maximum of 21 per compartment. The mean score of
three sections was calculated for each knee compart-
ment. To assess the global OA score, scores of each
compartment were added, giving a maximal score of 84.
Lateral and medial synovial membranes were also scored
(synovial lining cells hyperplasia 0–2, villous hyperplasia
Legrand et al. Arthritis Research & Therapy  (2018) 20:131 Page 3 of 16
0–3, degree of cellular infiltration by perivascular lym-
phocytes and mononuclear cells 0–5), and the mean of
lateral and median membrane was calculated to assess
the global synovial score (maximum score of 10) [11].
Biomechanical testing by Mach-1® micromechanical tester
The left knee joint (femoral condyles and tibial plateaus)
of each animal was used for testing the biomechanical
properties of articular cartilage assessed using a Mach-1®
micromechanical tester (Mach-1; Biomomentum Inc.,
Laval, QC, Canada) [12]. Prior to testing, samples were
thawed at room temperature in PBS for 30 minutes to
equilibrate before starting experiments. Subsequently, the
femoral condyle or tibial plateau was fixed with LOC-
TITE® 4013 glue (Henkel, Stamford, CT, USA) in a small
plastic container (Additional file 1: Figure S2). Through-
out the testing, each sample was kept moist with PBS.
Using top-view pictures of each sample, at least 50 posi-
tions per articular surface were tested using the automated
indentation and thickness-mapping protocol. The instant-
aneous modulus—a measure of cartilage stiffness and car-
tilage thickness—was calculated using the Mach-1 analysis
software (see Additional file 1).
Primary culture of human chondrocytes
Human chondrocytes were cultured in multilayers in
six-well plates and treated with interleukin-1β (IL-1β)
[13]. Chondrocytes were isolated from human articular
cartilage taken during the installation of total knee pros-
thesis. Cartilage samples were obtained from four adults
(two men and two women) whose mean age was 70 years
(range, 51–81 years). All specimens used were obtained
with informed consent. This procedure was approved by
the Ethics Committee of the Catholic University of Louvain
(project no. B403201214793). Full-depth articular cartilage
was excised and immersed in DMEM (with phenol red and
4.5 g/L glucose) supplemented with 4-(2-hydroxyethyl)-1--
piperazineethanesulfonic acid (HEPES) 10 mM, penicillin
100 U/ml, and streptomycin 0.1 mg/ml (all from Lonza,
Verviers, Belgium). After three washings, chondrocytes
were released from cartilage by sequential enzymatic diges-
tions with 0.5 mg/ml hyaluronidase type IV S (Sigma-Al-
drich, Bornem, Belgium) for 30 minutes at 37 °C, 1 mg/ml
pronase E (Merck, Leuven, Belgium) for 1 hour at 37 °C,
and 0.5 mg/ml collagenase from Clostridium histolyticum
type IA (Sigma-Aldrich) for 16 to 20 hours at 37 °C. The
enzymatically isolated cells were then filtered through a
nylon mesh (70 μm), washed three times, counted, and
filled to the density of 0.25 × 106 cells/ml of DMEM (with
phenol red and 4.5 g/L glucose) supplemented with 10%
FBS, 10 mM HEPES, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 2 mM glutamine (all from Lonza), and
20 μg/ml proline (Sigma-Aldrich). After 21 days of culture,
chondrocytes were treated in triplicate with recombinant
human IL-1β (1.7 ng/ml; Roche Pharmaceuticals, Brussels,
Belgium). The seeding density of the chondrocytes in the
six-well plates was 50,000 cells/cm2. There was no passage
of the cells; the cells overlap and form an extracellular
matrix. Culture medium and IL-1β treatment were replaced
at 3 and 6 days, and conditioned medium was removed at
3, 6, and 10 days and stored at − 20 °C until analysis.
Patients, healthy subjects, and sampling
Patient recruitment, characteristics, and sampling were
similar to those previously described [14]. Briefly, pa-
tients with early-stage OA (eOA) (n = 28), early-stage
rheumatoid arthritis (eRA) (n = 35), and inflammatory
joint disease other than rheumatoid arthritis (often
self-resolving) (non-RA) (n = 32) were recruited. Criteria
for eOA were subjects presenting with new-onset knee
pain, normal radiographs of the symptomatic knee, and
routine exploratory arthroscopy with macroscopic find-
ings classified as grade I/II on the Outerbridge scale, and
recruited at the Orthopaedic Clinics, University Hospital
Coventry & Warwickshire (UHCW), Coventry, UK. Pa-
tients with eRA and non-RA were recruited within
5 months of the onset of symptoms of inflammatory
arthritis at the Rapid Access Rheumatology Clinic, City
Hospital, Birmingham, UK. Synovial fluid and peripheral
venous blood samples were collected at initial presenta-
tion, and diagnostic outcomes were determined at
follow-up. Diagnosis of eRA was made according to the
1987 American Rheumatism Association criteria [15].
Diagnosis of non-RA was made when alternative rheum-
atological diagnoses explained the inflammatory arthritis
[16]. Criteria for these clinical classifications are similar
to those suggested in consensus position statements and
best practice statements [16, 17]. Healthy controls were
recruited at participating clinical centers (n = 29) at
UHCW. For healthy control subjects, inclusion criteria
were no history of joint symptoms, arthritic disease, or
other morbidity, and exclusion criteria were a history of
injury or pain in either knee, taking medication
(excepting oral contraceptives and vitamins), and any
abnormality at physical examination of the knee.
Recruitment of patients with advanced OA (n = 38)
immediately prior to total knee replacement (TKR) sur-
gery (advanced osteoarthritis [aOA], pre-TKR) was done
with written informed consent from patients referred for
TKR to the Norfolk and Norwich University Hospitals
NHS Trust (NNUH), Norwich, UK. Patients were
screened for study eligibility criteria as described previ-
ously [14]. Eligible patients were males or postmeno-
pausal females scheduled for TKR. This study was
approved by the National Research Ethics Service Com-
mittee East of England, Cambridge South, UK (approval
no. 2012ORTH06L [104-07-12]). All study procedures
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were performed in accordance with relevant laboratory
guidelines and institutional regulations.
Peripheral venous blood samples were collected with
ethylenediaminetetraacetic acid (EDTA) anticoagulant
from healthy subjects and patients with eOA after over-
night fasting. Venous blood samples for the eRA, non-RA,
and aOA study groups were collected in the nonfasted
state. For analytes studied, diurnal variation in plasma and
serum was 13–25%, depending on the analyte, as de-
scribed previously. Blood samples were centrifuged
(2000 × g, 10 minutes), and the plasma and synovial fluid
supernatant was removed and stored at − 80 °C until ana-
lysis. Samples were centrifuged within 1 hour of collec-
tion. Serum was available for eRA and non-RA study
groups, and plasma was used for all others. Serum was
comparable to plasma because nonprotein analytes were
assessed. To confirm this, venous blood samples were col-
lected with informed consent from human volunteers
(n = 6; 4 female, 2 male; age 47.8 ± 15.8 years; BMI 25.9 ±
4.0 kg/m2). Ethical approval was given by East Midlands
Regional Ethics Committee (reference 16/EM/0095).
Serum and plasma (with EDTA anticoagulant) was
prepared and assayed for the concentrations of glycated,
oxidized, and nitrated amino acids as described below.
There was no significant difference between analyte levels
in serum and plasma by Wilcoxon signed-rank test.
Analysis of glycated, oxidized, and nitrated protein and
amino acids in serum/plasma
Glycation, oxidation, and nitration adduct residues and
related precursor unmodified amino acid residues in
plasma/serum protein were quantified in exhaustive en-
zymatic digests, with correction for autohydrolysis of
hydrolytic enzymes [18, 19]. The concentrations of gly-
cated, oxidized, and nitrated amino acids (free adducts)
and hydroxyproline in plasma/serum were determined
similarly in 10 kDa ultrafiltrate of plasma/serum and cell
culture medium. Ultrafiltrate of plasma/serum (50 μl)
was collected by microspin ultrafiltration (10 kDa cutoff )
at 4 °C. Retained protein was diluted with water to
500 μl and washed in four cycles of concentration to
50 μl and dilution to 500 μl with water over the micro-
spin ultrafilter at 4 °C. The final washed protein (100 μl)
was delipidated and hydrolyzed enzymatically as de-
scribed previously [19, 20]. Protein hydrolysate (25 μl,
32 μg equivalent) or ultrafiltrate (5 μl) was mixed with
stable isotopic standard analytes (amounts as given pre-
viously) and analyzed by LC-MS/MS. Samples were ana-
lyzed using an ACQUITY™ ultra-high-performance
liquid chromatography system with a Xevo-TQS
LC-MS/MS mass spectrometer (Waters, Manchester,
UK). Samples are maintained at 4 °C in the autosampler
during batch analysis. The columns were 2.1 × 50-mm
and 2.1 × 250-mm, 5-μm particle size Hypercarb™
(Thermo Fisher Scientific, Waltham, MA, USA) in series
with programmed switching at 30 °C. Chromatographic
retention was necessary to resolve oxidized analytes
from their amino acid precursors to avoid interference
from partial oxidation of the latter in the electrospray
ionization source of the mass spectrometric detector.
Analytes were detected by electrospray positive
ionization and mass spectrometry multiple reaction
monitoring (MRM) mode, where analyte detection re-
sponse was specific for mass/charge ratio of the analyte
molecular ion and major fragment ion generated by
collision-induced dissociation in the mass spectrometer
collision cell. The ionization source and desolvation gas
temperatures were 120 °C and 350 °C, respectively; cone gas
and desolvation gas flow rates were 99 and 900 L/h; and the
capillary voltage was 0.60 kV. Argon gas (0.5 Pa) was in the
collision cell. For MRM detection, molecular ion and frag-
ment ion masses and collision energies optimized to ±
0.1 Da and ± 1 eV, respectively, were programmed [19]. In
all sample analyses, the investigator was blinded from the
sample identity. Analytes determined were as follows:
glycation adducts Nε-fructosyl-lysine (FL), Nε-carbo-
xymethyl-lysine (CML), Nε-carboxyethyl-lysine (CEL),
Nω-carboxymethylarginine (CMA), glyoxal-derived hydroi-
midazolone (G-H1), methylglyoxal-derived hydroimidazo-
lone (MG-H1), 3-deoxyglucosone-derived hydroimidazolone
isomers (3DG-H), GSP, and pentosidine; oxidation adducts
dityrosine (DT), N-formylkynurenine (NFK), α-aminoadipic
semialdehyde (AASA), and glutamic semialdehyde (GSA); ni-
tration adduct 3-nitrotyrosine (3-NT); and related amino
acids [19] (see Fig. 1 for structures and expansion of acro-
nyms). The biochemical and clinical significance is described
elsewhere [6]. Protein adduct residues (normalized to their
amino acid residue precursors; mmol/mol amino acid
modified) and serum or plasma free adduct concentrations
(μM or nM) are given. In culture medium, free adduct con-
centrations were corrected for cell number by normalizing to
cellular DNA content.
Citrullinated protein and hydroxyproline
Serum citrullinated protein (CP) and Hyp were analyzed
by stable isotopic dilution analysis LC-MS/MS, as pre-
viously described [20].
Machine learning
We developed algorithms using the clinical analyte data
to distinguish the following four groups of subjects and
patients: healthy control, eOA, eRA, and non-RA. The
diagnostic algorithms were trained on the dataset using
support vector machines [21]. The algorithm was vali-
dated by twofold cross-validation using five randomized
repeat trials for improved robustness. A two-stage ap-
proach was taken: (1) to distinguish between disease and
healthy control and (2) to distinguish between eOA,
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eRA, and non-RA. We used accuracy of case and control
classification to optimize algorithm features. Diagnostic
characteristics, including area under the ROC (AUROC),
are given with 95% CI determined via bootstrap analysis.
The contribution of each feature in the algorithms to
classification accuracy was assessed by determining the
change in AUROC when a feature was omitted from the
algorithm and retrained; a negative change represents a
valuable feature, and a positive change an adverse fea-
ture, for classification accuracy. Data were analyzed
using MATLAB version R2017A software (MathWorks,
Natick, MA, USA).
Statistical analysis
Results are expressed as mean ± SEM unless otherwise
stated. Following a normality test, one-way analysis of
variance (ANOVA) with Tukey’s posttest was performed
for histology, MACH-1, and amino acid analytes. Pear-
son’s correlations were performed between global OA
score, parameters of MACH-1, and amino acid
biomarkers. Given the asymmetric distribution of bio-
markers, a logarithmic transformation was considered to
satisfy the hypothesis of normality. ANOVA was applied
to compare each biomarker between age groups. The
same analysis was used to compare the different parame-
ters between age groups. The association between the
log-transformed biomarkers and the parameters was
assessed by Pearson’s correlation. A multiple regression
model (including as independent variables age, the par-
ameter of interest, and an interaction term between
these two factors) was constructed in order to in-
vestigate the influence of this parameter in the
biomarker-age relationship (potential confounding fac-
tor). The results were considered to be significant at the
5% critical level (p < 0.05). There was no repeated ana-
lysis of the guinea pigs or human subjects, so repeated
measures analysis is not applicable. For longitudinal ana-
lysis of multilayer cultures, to investigate a possible dif-
ference between the two groups, a mixed model with an
undefined covariance matrix was applied to the data.
The independent variables considered in this model
were time, IL-1β treatment, and interaction between
them. This statistical approach allowed us to compare
biomarker production curves between the two groups
while taking into account the presence of correlated
data. For significance tests and correlation analysis of 14
glycated, oxidized, and nitrated amino acids and hy-
droxyproline analyzed in serum filtrate and 14 glycation,
oxidation, and nitration adduct residues and CP in
serum protein (15 analytes in each sample type),
analyzed without preconceived hypothesis, a Bonferroni
correction of 15 was applied. The predictive ability of
these analytes for development of OA was studied by de-
veloping a partial least squares (PLS) regression model.
The model was trained to learn to predict OA histo-
logical score from concentrations of serum glycated, oxi-
dized, and nitrated amino acids (FL, CML, CEL,
MG-H1, G-H1, 3DG-H, CMA, AASA, GSP, GSA, NFK,
DT, 3-NT, pyrraline, Hyp, and CP) with the 4–36 weeks
guinea pig study groups. Subsequent to training, the
model was used to predict OA histological score for
each guinea pig. The residual error between model
predictions and the actual OA histological score was
estimated as root mean squares error. Error at each indi-
vidual stage and the overall error at all stages were esti-
mated. Data analysis was performed with SAS version
9.4 for Windows statistical software (SAS Institute, Cary,
NC, USA).
Results
Spontaneous OA in Dunkin-Hartley guinea pig
All 60 guinea pigs were examined daily during the study.
Two guinea pigs died at study weeks 30 and 31. Guinea
pig body weights at the time the animals were killed
were (in grams, mean ± SD): week 4, 282 ± 9; week 12,
723 ± 54; week 20, 887 ± 61; weak 28, 978 ± 78; and week
36, 1016 ± 80. During the study, the five groups showed
similar gains in body weight, with no difference observed
between study groups of the same age. Food con-
sumption declined progressively with guinea pig age (see
Additional file 1). The liver and kidney were examined
after animals were killed. No abnormalities were ob-
served; the liver and adrenal gland weights were similar
between guinea pigs of the same study group.
Histological assessment of cartilage lesions as recom-
mended by OARSI showed that guinea pigs spontan-
eously developed severe knee OA (Fig. 2). In all animals,
the global histological score increased significantly with
age until week 28 and then stabilized between weeks 28
and 36 (Fig. 3a). A significant and progressive increase
of synovial score between weeks 4 and 36 was observed
(Fig. 3b). The global histological score correlated posi-
tively with the global synovial histological score (r = 0.55,
p < 0.001).
Cartilage thickness and biomechanical properties were
assessed by the Mach-1® micromechanical tester. Cartil-
age thickness of the knee joint was decreased at the con-
dyle and tibial plateau regions from 12 to 20 weeks and
remained at a stable low level thereafter (Fig. 3c and d).
Instantaneous modulus of the articular cartilage in-
creased progressively in the condyle at weeks 12 and 20
and remained at a stable high level thereafter, and it in-
creased progressively from weeks 20 to 36 in the tibial
plateau region (Fig. 3e and f). There were negative cor-
relations of condyle and tibial plateau cartilage thickness
with increased OA histological score and positive corre-
lations with instantaneous modulus (Fig. 3g–j). Detailed
histological analysis showed that the structure of the
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cartilage and the proteoglycan content correlated
with the instantaneous modulus of the femoral con-
dyle (r = 0.58, p < 0.001; r = 0.52, p < 0.001). At the
tibial plateaus, the strongest associations were found
between the cartilage structure and integrity of tidemark
and the instantaneous modulus (r = 0.44, p < 0.002; r = 0.43,
p < 0.002, respectively).
Analysis of glycated, oxidized, and nitrated amino acids
and protein in serum
For glycated amino acids, serum concentrations of FL,
CEL, and G-H1 were unchanged from 4 to 28 weeks
and then increased two- to threefold at week 36 when
OA was severe (Fig. 4a–c). Pyrraline free adduct was de-
creased at weeks 20 and 28 compared with 4, 12, and
36 weeks (Fig. 4d). Pyrraline is an advanced glycation
endproduct (AGE) sourced exclusively from food, which
may explain this disparate time-course profile [22].
CMA free adduct showed a similar trend (Fig. 4e). CML,
MG-H1, and 3DG-H free adducts initially decreased at
12 and 20 weeks compared with the 4-week baseline
levels, returned to baseline levels at 28 weeks, and then
increased two- to threefold at 36 weeks (Fig. 4f–h). In
contrast, GSP free adduct was unchanged at 12 weeks
and then increased progressively from 20 to 36 weeks to
threefold higher than baseline levels (Fig. 4i).
For oxidized amino acids, serum DT, NFK, and GSA
free adducts increased progressively from 28 to 36 weeks
to two- to threefold higher than baseline levels, increasing
slightly later in OA development than GSP (Fig. 4j–l).
AASA free adduct was decreased at 12 weeks and in-
creased at 36 weeks (Fig. 4m). Serum 3-NT concentration
was decreased by 29–32% at 12–36 weeks compared with
baseline (Fig. 4n).
For OA-linked markers, bone resorption marker
serum Hyp was decreased at weeks 12–28 with
Fig. 2 Representative pictures of medial compartment of right guinea pig knees of each group over time. Safranin-O/Fast Green/hematoxylin
staining, 4 × magnification. W4–W36 (week 4 – week 6) inset indicates the age of the guinea pig donor analyzed
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Fig. 3 (See legend on next page.)
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respect to baseline level, and serum CP was decreased
by 50–71% from weeks 20 to 36 (Fig. 4o and p).
For glycation, oxidation, and nitration of serum pro-
tein, most adduct residue contents decreased from 12
to 20 weeks and remained decreased thereafter, ex-
ceptions being glycation adducts FL and pentosidine
and oxidation adduct DT, which increased (see
Additional file 1). Changes of serum free adducts and
serum protein adducts are summarized in heat maps
(Fig. 4q and r).
In correlation analysis, most serum glycation and oxi-
dation free adducts were correlated with each other, the
correlations being driven mainly by the marked increase
of most analytes at 36 weeks. Exceptions were positive
(See figure on previous page.)
Fig. 3 Development of osteoarthritis in Dunkin-Hartley guinea pigs. a Total OA score at four sites in each group. b Global synovial histological score in
each group. Horizontal bars indicate median values. c Correlation of global synovial histological score with total OA score (r = 0.55, p = 7 × 10− 6;
Spearman). Thickness (in millimeters) (d and e) and instantaneous modulus (MPa) (f and g) in femoral condyles and tibial plateau, respectively. Data
are mean ± SEM (n = 12 in each group, except n = 10 at week 36). h–k Correlations of cartilage thickness and instantaneous modulus on global OA
histological score in condyle and tibial plateau. Correlation coefficients are (h) r = − 0.35, p < 0.01; (i) r = − 0.27, p < 0.05; (j) r = 0.58, p < 0.001; and (k) r =
0.44, p < 0.002. Significance (a–f): * p < 0.05; ** p < 0.01; and *** p < 0.001 with respect to 4-week study group; o, oo, and ooo, p < 0.05, p < 0.01, and
p < 0.001 with respect to 12-week study group; and # p < 0.05 with respect to 20-week study group; one-way analysis of variance with Tukey posttest
Fig. 4 Serum protein glycation, oxidation, and nitration adducts and hydroxyproline and citrullinated protein during development of
osteoarthritis in Dunkin-Hartley guinea pigs. Left side, center panels: Time course changes of serum glycation, oxidation, and nitration free
adducts. a Nε-Fructosyl-lysine (FL). b Nε(1-carboxyethyl)lysine (CEL). c glyoxal-derived hydroimidazolone (G-H1). d Pyrraline. e Nω-carboxymethylarginine
(CMA). f Nε(1-carboxymethyl)lysine (CML). g Methylglyoxal-derived hydroimidazolone (MG-H1). h 3-Deoxyglucosone-derived hydroimidazolone
(3DG-H). i Glucosepane (GSP). j Dityrosine (DT). k N-formylkynurenine (NFK). l Glutamic semialdehyde (GSA). m α-Aminoadipic semialdehyde (AASA).
(n) 3-Nitrotyrosine (3-NT). Other serum markers were Hydroxyproline (Hyp) (o) and citrullinated protein (CP) (p). Data are mean ± SEM. Significance: *
p < 0.05, ** p < 0.01 and *** p < 0.001 by one-way analysis of variance with Tukey posttest. Right side panels: Heat map representation of changes: q
serum glycation, oxidation, and nitration free adducts and Hyp. r Serum protein glycation, oxidation, and nitration adduct residues and CP
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correlations of pyrraline with CMA and 3-NT free ad-
ducts and a negative correlation with NFK, and positive
correlation of serum Hyp with CML. There were no
correlations of glycation, oxidation, and nitration free
adducts with serum CP. In contrast, serum CP corre-
lated positively with levels of most glycation, oxidation,
and nitration adduct residues of serum protein, except
for FL and DT, where the correlations were negative (see
Additional file 1).
For associations of protein glycation, oxidation, and ni-
tration free adducts with the global histological score,
GSP, AASA, GSA, DT, and NFK correlated positively with
global histological score after correction for multiple ana-
lyte measurements. GSP had the highest correlation coef-
ficient and significance (r = 0.58, p < 0.0001). In contrast,
3-NT free adduct correlated negatively with the global
histological score. For cartilage thickness, 3-NT and Hyp
correlated positively, and GSA negatively, at condyle and
tibial plateau sites. Hyp had the highest correlation coeffi-
cient and significance (condyle r = 0.47, p = 0.0003; plateau
r = 0.39, p = 0.003). Six free adducts correlated positively
with instantaneous modulus; GSP had the highest correl-
ation coefficient and significance (condyle r = 0.52 and
plateau r = 0.56; p < 0.0001). CMA and 3-NT free adducts
and CP correlated negatively with instantaneous
modulus; 3-NT free adduct (condyle r = − 0.46, p = 0.0004;
plateau r = − 0.41, p = 0.003) and CP (femoral condyle
r = − 0.53, p < 0.0001), remaining significant after
Bonferroni correction (Table 1).
A PLS regression model of serum glycated, oxidized, and
nitrated amino acids, Hyp, and CP on total OA histological
score was computed. After training, the model was used to
predict total OA histological score for each guinea pig. The
outcome indicated that the model predicted histological
score well in the early development of OA (4, 12, and
20 weeks) with declining predictive performance in more
advanced stages (28 and 36 weeks) (see Additional file 1).
Multilayer primary human chondrocytes culture
From days 6 through 10, the production of CEL, G-H1,
CMA, GSP, NFK, and 3-NT was increased with IL-1β
treatment compared with control. In mixed model statis-
tical study, all amino acid analytes increased over time,
and increases of G-H1, CEL, and 3-NT were higher with
IL-1β treatment compared with the control (Fig. 5).
Plasma/serum glucosepane free adduct in clinical OA and
application for clinical diagnosis and typing of early-stage
arthritis of the knee
With the emergence of serum GSP free adduct as a poten-
tial marker of OA from the guinea pig study and chondro-
cyte studies, we analyzed serum GSP in patients and
healthy controls, including a study group with aOA,
pre-TKR surgery. Clinical characteristics were presented
previously [14, 20]. Plasma GSP free adduct was increased
38% in eOA, sixfold in aOA, pre-TKR, twofold in
non-RA, and threefold in eRA (Table 2). Developing diag-
nostic algorithms for early-stage arthritic disease, we
found that optimum performance to discriminate between
healthy controls and early-stage arthritis of any type was
achieved with features in the algorithm: serum Hyp, glyca-
tion free adducts (CEL, GSP, MG-H1, 3DG-H, G-H1, and
Table 1 Correlation of glycation, oxidation, and nitration free adducts and citrullinated protein with global histological score and
joint biomechanical properties measured by Mach-1 parameters
Global histological
score
Thickness Instantaneous modulus
Condyle Plateau Condyle Plateau
r p Value r p Value r p Value r p Value r p Value
Glycation FL 0.33 0.012 0.30 0.031
G-H1 0.26 0.046
CMA − 0.32 0.017
3DG-H 0.27 0.044
GSP 0.58 < 0.0001a 0.52 < 0.0001a 0.56 < 0.0001a
Oxidation AASA 0.38 0.0029a 0.27 0.043 0.40 0.004
GSA 0.36 0.0062a − 0.29 0.033 − 0.33 0.015 0.35 0.013
Dityrosine 0.42 0.0009a 0.34 0.010 0.36 0.010
NFK 0.42 0.0011a 0.37 0.006 0.33 0.018
Nitration 3-NT − 0.46 0.0003a 0.33 0.013 0.29 0.034 − 0.46 0.0004a − 0.41 0.003a
Hyp 0.47 0.0003a 0.39 0.003a − 0.38 0.0037
CP − 0.52 < 0.0001a − 0.53 < 0.0001a − 0.33 0.018
Abbreviations: FL Nε-fructosyl-lysine, G-H1 Glyoxal-derived hydroimidazolone, CMA Nω-carboxymethylarginine, 3DG-H 3-Deoxyglucosone-derived hydroimidazolone
isomers, GSP Glucosepane, AASA α-Aminoadipic semialdehyde, GSA Glutamic semialdehyde, NFK N-formylkynurenine, 3-NT 3-Nitrotyrosine, Hyp Hydroxyproline, CP
Citrullinated protein
aCorrelation coefficient significant after Bonferroni correction of 15 was applied
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CMA), oxidation free adducts (NFK, methionine sulfoxide
[MetSO], and DT), and nitration free adduct 3-NT
(Algorithm 1). This had sensitivity 90.4%, specificity
83.2%, and AUROC 0.93; random selection is 0.50. In
assessing the relative importance of each feature in classi-
fication accuracy, ΔAUROC on feature omission was
(largest to smallest): CEL, − 0.067; GSP, − 0.063; Hyp, −
0.026; NFK, − 0.024; MetSO, − 0.014; MG-H1, − 0.011;
3DG-H, − 0.009; G-H1, − 0.008; 3-NT, − 0.004; DT, −
0.0005; and CMA, − 0.00008.
In a subsequent step for patients with early-stage arth-
ritis, optimum performance to discriminate between types
of arthritis included features in the algorithm: anti-CCP-Ab
positivity assessment with glycation free adducts (3DG-H,
CML, FL, GSP, and CEL) and oxidation and nitration free
adducts (MetSO and 3-NT, respectively). This distinguished
eOA from eRA and non-RA with sensitivity 94.0%, specifi-
city 96.1%, and AUROC 0.98; random selection is 0.33
(Table 3 and Additional file 1). In assessing relative import-
ance of each feature in classification accuracy, mean
Fig. 5 Concentrations of glycation, oxidation, and nitration free adducts in multilayer culture supernatant. Analyte concentrations in the culture
medium, normalized to cell DNA content. Key: dashed lines = control; solid lines = + IL-1β. Free adduct: a FL. b CML. c CEL. d G-H1. e MG-H1.
f CMA. g GSP. h AASA. i GSA. j DT. k NFK. l 3-NT. Data are mean ± SEM (n = 4). * p < 0.05, ** p < 0.01, and *** p < 0.001. Through longitudinal
statistical study, we found that all biomarkers increased significantly over time (p < 0.0001). Comparison of the time-course curves showed that
levels of G-H1, CEL, and 3-NT were increased with IL-1β treatment compared with control (p = 0.0023, p = 0.0071, and p < 0.0001, respectively)
Table 2 Plasma or serum glucosepane free adduct in patients with early and advanced osteoarthritis and other early-stage arthritic
disease
Study group No. Age (yr) Gender (M/F) Glucosepane (nM)
Control 29 34.4 ± 8.2 14/15 13.6 (10.1–18.1)
eOA 28 43.3 ± 13.3* 12/16 18.7 (13.3–35.5)*,OOO
aOA, pre-TKR 38 70.7 ± 8.9*** 15/23 76.3 (61.2–97.5)***
Non-RA 32 51.7 ± 18.1** 14/16 31.2 (20.3–45.2)**,OOO
eRA 35 60.4 ± 15.7*** 13/22 46.1 (31.1–77.8)***,OOO
Abbreviations: eOA Early-stage osteoarthritis, aOA Advanced osteoarthritis, TKR Total knee replacement, RA Rheumatoid arthritis, eRA Early-stage
rheumatoid arthritis
Data are median (lower – upper quartile). Significance: 5-group comparison – p < 0.001 (Kruskal-Wallis). For binary comparisons: *, ** and ***, p < 0.05, p < 0.01 and
p < 0.001 with respect to plasma levels of healthy controls; ooo, p < 0.001 with respect to plasma levels of aOA, pre-TKR (Mann-Whitney U)
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ΔAUROC on feature omission for the three classifications
was as follows: anti-CCP antibody status, − 0.116; 3DG-H,
− 0.089; CML, − 0.082; FL, − 0.073; GSP, − 0.066; MetSO, −
0.034; CEL, − 0.027; and 3-NT, − 0.023.
Discussion
In this study, we showed that serum concentrations of
trace-level glycated, oxidized, and nitrated amino acids
increase with development of OA in an experimental
spontaneous model of knee joint OA. Multiple regres-
sion models, adjusted for body weight, suggested that
these changes were not due to changes in body weight.
GSP free adduct emerged as a biomarker that strongly
and positively correlated with global OA histological
score and instantaneous modulus measure of stiffness of
articular cartilage, increasing with OA severity. Plasma
GSP free adduct was modestly and markedly increased
in early-stage and severe, advanced clinical OA, respect-
ively. Inclusion of plasma GSP free adduct in a diagnos-
tic algorithm with other trace-level glycated, oxidized,
and nitrated amino acids improved detection and arth-
ritis type classification of early-stage clinical OA. We
also found that IL-1β, a key cytokine involved in OA
pathogenesis, increased the release of GSP and other
glycation, oxidation, and nitration free adduct release
from chondrocytes, suggesting that inflammation-driven
proteolysis may increase free adduct release in vivo. This
provides further evidence that, taken together with our
previous reports [5, 10, 20], suggests that measurement
of trace-level damaged amino acids in serum or plasma
are potential biomarkers for diagnosis, progression of
severity and therapeutic monitoring in OA and other
arthritic disease.
In advanced OA in guinea pigs at 36 weeks, serum
concentrations of glycated and oxidized amino acids
were increased compared with week 4 control, except
for pyrraline, CMA, and 3-NT. From previous studies of
Dunkin Hartley guinea pigs, the development of knee
joint cartilage, proteoglycan, and bone structure is
mature at 12 weeks [23]. Beyond this time, there is
increased cartilage density associated with change in car-
tilage crosslink structure, and from 28 weeks, increased
degradation of cartilage [24, 25]. Previous studies found
increased markers of cartilage degradation, keratan
sulfate, cartilage oligomeric matrix protein, and
collagenase-generated fragments of collagen II [26] as
well as markers of bone metabolism (urinary
hydroxylysyl-pyridinoline and lysyl-pyridinoline, and
serum osteocalcin), consistent with this [27]. We
suggest that increases in glycated and oxidized
amino acids are due to enhanced proteolysis of
articular cartilage and bone remodeling, leading to
increased flux of release of glycation and oxidation
free adducts into the vasculature for urinary excre-
tion. There is also an expected contribution from
increased uptake of some glycated amino acids from
food for some analytes (see below). Increased gly-
cated and oxidized amino acid release from cartilage
may occur without further change in its thickness
through increased cartilage turnover and/or swelling
[28]. The earlier increase in serum GSP from week
20 may relate to restructuring and decrease of carti-
lage crosslinks found during this period.
Pyrraline is an AGE derived only from food [22] and hence
provides an objective biomarker of food consumption [29].
Serum CMA free adduct correlated positively with pyrraline
Table 3 Characteristics of diagnostic algorithms for diagnosis and typing of early-stage arthritis: predictive algorithm outcomes for
twofold cross-validation
Algorithm features Algorithm 1: plasma Hyp and GSP, G-H1, MG-H1,
3DG-H, CEL, CMA, MetSO, 3-NT, NFK, and DT free adducts
Algorithm 2: anti-CCP-Ab positivity assessment and plasma
GSP, FL, 3DG-H, CML, CEL, MetSO, and 3-NT free adducts
Classification Disease vs control eOA vs non-RA
and eRA
eRA vs non-RA
and eOA
Non-RA vs eRA
and eOA
Accuracy (%) 88.4 (86.9–90.0) 95.5 (93.7–97.3) 78.1 (74.3–82.0) 78.9 (74.7–83.2)
Sensitivity (%) 90.4 (88.7–92.1) 94.0 (88.8–99.3) 69.1 (54.4–83.7) 67.5 (46.2–88.8)
Specificity (%) 83.2 (77.4–89.0) 96.1 (92.6–99.6) 83.2 (71.8–94.6) 84.6 (77.1–92.1)
AUROC 0.93 (0.92–0.94) 0.98 (0.97–0.99) 0.86 (0.81–0.90) 0.88 (0.86–0.90)
Positive likelihood ratio 8.26 (5.77–10.75) 16.11 (9.56–22.66) 7.66 (2.94–12.37) 4.96 (3.31–6.60)
Negative likelihood ratio 0.11 (0.10–0.13) 0.06 (0.01–0.11) 0.34 (0.20–0.48) 0.36 (0.14–0.57)
Positive predictive value (%) 93.6 (91.7–95.6) 92.8 (86.5–99.0) 76.3 (65.1–87.4) 71.8 (62.7–80.8)
Negative predictive value (%) 77.3 (74.4–80.2) 97.5 (95.3–99.6) 84.4 (79.0–89.8) 86.2 (78.9–93.4)
F-score 0.92 (0.91–0.93) 0.93 (0.90–0.96) 0.69 (0.62–0.75) 0.64 (0.49–0.79)
Abbreviations: MetSO Methionine sulfoxide, FL Nε-fructosyl-lysine, G-H1 Glyoxal-derived hydroimidazolone, MG-H1 Methylglyoxal-derived hydroimidazolone, CMA
Nω-carboxymethylarginine, 3DG-H 3-Deoxyglucosone-derived hydroimidazolone isomers, GSP Glucosepane, NFK N-formylkynurenine, 3-NT 3-Nitrotyrosine, Hyp
Hydroxyproline, eOA Early-stage osteoarthritis, TKR Total knee replacement, RA Rheumatoid arthritis, eRA Early-stage rheumatoid arthritis, DT Dityrosine, CCP
Cyclic citrullinated peptide, CML Nε-carboxymethyl-lysine, CEL Nε-carboxyethyl-lysine
Data are mean (95% CI). Analyte data other than GSP (Table 2) employed in algorithm development were reported previously [5]
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and may be sourced mainly from the diet in this study. There
was a progressive decline in food consumption by the guinea
pigs from week 4 to week 36. Gait and mobility are impaired
in advanced OA in this model [30], but in the present study
decreased food consumption may have been linked to pain
with loss of appetite and decreased voluntary activity. The
guinea pigs typically show a progressive increase in body
weight [31], as found in the present study (see Add-
itional file 1). Serum pyrraline free adduct concentration
showed a trend similar to that of food consumption with de-
creases at weeks 20 and 28, diverging from this with an
anomalous increase at week 36. CML, MG-H1, and 3DG-H
usually have significant contributions from the diet [29, 32,
33]. The decreases of serum CML, MG-H1, and 3DG-H free
adduct concentrations at 12 weeks may be related to the ini-
tial decline in food consumption. Progressive decreased food
consumption may explain decreases in serum CMA, CML,
MG-H1, and 3DG-H free adduct concentrations at 20 weeks,
as well as decreases in serum CMA and MG-H1 at 28 weeks.
The lack of decrease in serum CML and 3DG-H free adduct
concentrations at 28 weeks may relate to increasing release
of these analytes from the joints with increasing OA progres-
sion. Reversal of the decrease in serum pyrraline concentra-
tion at 36 weeks is not linked to food consumption, but
rather to increased efficiency of uptake of pyrraline from
ingested food, likely mediated by increased intestinal amino
acid transporter activity. Similar increased dietary uptake of
CMA, CML, MG-H1, and 3DG-H is expected and may con-
tribute to the increases of these serum analytes at 36 weeks.
The mechanism by which this occurs merits further
investigation.
The negative correlations of serum 3-NT free adduct
with global histological score and condyle and plateau in-
stantaneous modulus may be due to changes in 3-NT free
adduct from digestion of nitrated proteins in the ingested
chow and decreased food intake as OA developed because
serum 3-NT free adduct correlated positively with serum
pyrraline free adduct. A similar but more limited effect
was found for serum CMA free adduct.
The amino acid analytes with strongest correlation to
histological and biomechanical features of developing OA
were GSP and DT free adducts. GSP is formed by degrad-
ation of FL residues and subsequent proteolysis of
GSP-modified protein. Although GSP is present in food
proteins, it is not usually absorbed from the diet. The
strong link of serum GSP free adduct concentration to glo-
bal OA histological score and cartilage stiffness is likely due
to GSP being of an exclusive endogenous source, a major
protein crosslink and formation by joint proteolysis. This
also translated to increase plasma or serum levels of GSP in
clinical OA. Serum DT free adduct may have emerged as a
biomarker of global OA histological score for similar rea-
sons and also its likely increased formation associated with
inflammation.
We also measured protein glycation, oxidation, and
nitration adduct residues and citrullination in serum
protein during OA development. These showed mark-
edly different changes with age (cf. Fig. 4q and r).
This demonstrates the importance of analyzing pro-
tein glycation residues and free adduct separately.
Most protein modifications were decreased as OA
developed. Exceptions were FL, pentosidine, and DT.
The concurrent decrease of many different modifica-
tions suggests the underlying cause may be increased
capillary permeability with increased residence time of
albumin in the interstitial fluid, where protein
concentration and rates of protein modification are
usually lower than in the vascular compartment [34].
Increased capillary permeability may be driven by
increased inflammatory reaction from 3 to 12 weeks
of age in this guinea pig model [35] and also by in-
creased prostaglandin E2, a dilatator of blood vessels
[10]. Levels of FL and pentosidine may be increased
by decline in glucose tolerance related to insulin
resistance driven by increased IL-1β [35], producing
increased early-stage protein glycation and increased
pentose-derived metabolite precursors of pentosidine
[36]. The anomalous increase in DT while other
oxidative markers are decreasing suggests a specific
effect. Formation of DT occurs enzymatically by dual
oxidase (DUOX) [37]. DUOX expression is increased
through activation of activating transcription factor
2in inflammatory signaling [38]. Similar effects were
found previously in plasma and synovial fluid protein
in clinical early- and advanced-stage OA [5, 20]. This
is a likely consequence of systemic low-grade inflam-
mation in OA and indicates relevance of the
Dunkin-Hartley guinea pig model of OA for clinical
translation.
Serum CP decreased as OA developed in Dunkin-Hartley
guinea pigs. The mechanism of this remains unclear, but it
corroborates with our earlier clinical studies where there
was higher plasma CP in patients with eOA than in pa-
tients with aOA [20]. The increased inflammatory media-
tors in OA are thought to reach their zenith in early-stage
disease and then decrease in advanced disease [39]. Inflam-
matory mechanisms linked to CP formation through ex-
pression of protein arginine deiminases may be a
component of this and may explain the decline of serum
CP in advanced OA.
We studied the effect of IL-1β on flux of protein glyca-
tion, oxidation, and nitration, as judged by increased
concentration of protein glycation, oxidation, and nitration
free adducts in culture medium. IL-1β increased flux of for-
mation of CEL, G-H1, CMA, GSP, DT, NFK, and 3-NT.
This model was not confounded by change in uptake of
protein glycation, oxidation, and nitration free adducts (cf.
effects in Dunkin-Hartley guinea pigs). The upper limit of
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the concentration of IL-1β in human synovial fluid is about
20 pg/ml in patients with severe knee OA [40]. We used a
higher concentration, as previously [41–43], to model the
effects of continuous exposure to IL-1β in vivo at the
steady-state concentration, with additions at 3-day intervals
and half-life of 2.5 hours of IL-1β [44].
We applied plasma or serum glycated, oxidized, and
nitrated amino acid with Hyp and anti-CCP antibody sta-
tus for diagnosis and type of early-stage arthritic disease.
For classification of good vs early-stage arthritic disease
(any), the relative importance of algorithm features was as
follows: CEL > GSP >Hyp >NFK >MetSO > MG-H1 >
3DG-H >G-H1 > 3-NT >DT > CMA. The high import-
ance of GSP corroborates with the early changes in serum
GSP free adduct found in experimental spontaneous OA
in the present study, and the importance of Hyp corrobo-
rates results of our earlier studies [20]. The importance of
methylglyoxal-derived AGEs, CEL, and MG-H1 is a new
development and supports the emergence of the role of
dicarbonyl stress in aging and chronic disease [45]. For
classification of early-stage arthritic disease, the relative
importance of algorithm features was as follows: anti-CCP
antibody positivity > 3DG-H >CML > FL > GSP >MetSO
> CEL > 3-NT. This reflects the high prevalence of
anti-CCP antibody positivity in eRA. The three next most
important features are glycation adducts, which may also
suggest there are distinct contributions of glycation to
eOA, eRA, and non-RA. Combination of estimates of
serum trace-level glycated, oxidized, and nitrated amino
acids and Hyp may therefore improve diagnosis of
early-stage arthritic disease, including progression of ex-
perimental spontaneous OA, as supported by predictions
with the PLS regression model.
Conclusions
We conclude that trace-level damaged amino acids in
serum may be valuable biomarkers in OA, particularly
GSP.
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